TGFB1 and liver dysplastic nodule: Thus, clinical treatment using the antibody-based strategies should be cautious since most circulating TGF-β1 is in latent form, and administration of anti-TGF-β antibody may block the beneficial effect of latent TGF-β1 and result in an adverse effect on patients with DN.